The Bowel Research Collaborative Data Tracking System Implementation Study
NCT00728975
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Patients receiving palliative care
- None
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Vancouver, British Columbia
- Birmingham, Alabama
- Chandler, Arizona
- Mesa, Arizona
- Mesa, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Tempe, Arizona
- Tucson, Arizona
- Tucson, Arizona
- Hot Springs, Arkansas
- Garden Grove, California
- Laguna Hills, California
- Los Gatos, California
- Newport Beach, California
- Newport Beach, California
- Colorado Springs, Colorado
- Boca Raton, Florida
- Brandon, Florida
- Chiefland, Florida
- Clearwater, Florida
- Daytona Beach, Florida
- Fort Myers, Florida
- Gainesville, Florida
- Jacksonville, Florida
- Jacksonville, Florida
- Jupiter, Florida
- Miami, Florida
- Miami, Florida
- Ocala, Florida
- Ocala, Florida
- Ocala, Florida
- Orlando, Florida
- Ormond Beach, Florida
- Port Orange, Florida
- Sarasota, Florida
- Sarasota, Florida
- Tampa, Florida
- Tampa, Florida
- Vero Beach, Florida
- Winter Park, Florida
- Chicago, Illinois
- Rockford, Illinois
- Avon, Indiana
- Evansville, Indiana
- Indianapolis, Indiana
- Indianapolis, Indiana
- West Des Moines, Iowa
- Madisonville, Kentucky
- Hagerstown, Maryland
- Hollywood, Maryland
- Boston, Massachusetts
- Brockton, Massachusetts
- Watertown, Massachusetts
- Bingham Farms, Michigan
- Chesterfield, Michigan
- Kalamazoo, Michigan
- Traverse City, Michigan
- Edina, Minnesota
- Biloxi, Mississippi
- Jackson, Mississippi
- Springfield, Missouri
- Omaha, Nebraska
- Henderson, Nevada
- Las Vegas, Nevada
- Las Vegas, Nevada
- Las Vegas, Nevada
- Elizabeth, New Jersey
- Albuquerque, New Mexico
- Great Neck, New York
- New York, New York
- Charlotte, North Carolina
- Raleigh, North Carolina
- Fargo, North Dakota
- Centerville, Ohio
- Dayton, Ohio
- Oklahoma City, Oklahoma
- Medford, Oregon
- Portland, Oregon
- Altoona, Pennsylvania
- Levittown, Pennsylvania
- Yardley, Pennsylvania
- Cranston, Rhode Island
- Huntingdon, Tennessee
- Austin, Texas
- Beaumont, Texas
- Dallas, Texas
- Dallas, Texas
- Houston, Texas
- Hurst, Texas
- San Antonio, Texas
- San Antonio, Texas
- Salt Lake City, Utah
- Christiansburg, Virginia
- Bellevue, Washington
- Broadmeadow, New South Wales
- Edmonton, Alberta
- Kelowna, British Columbia
- Vancouver, British Columbia
- Winnipeg, Manitoba
- Mount Pearl, Newfoundland and Labrador
- Dartmouth, Nova Scotia
- Hamilton, Ontario
- London, Ontario
- Oshawa, Ontario
- Sarnia, Ontario
- Toronto, Ontario
- Mirabel, Quebec
- Sainte-Foy, Quebec
- Sherbrooke, Quebec
- St-Romuald, Quebec
- Trois-Rivieres, Quebec
- Quebec,
- Barranquilla, Atlantico
- Bogota, Cundinamarca
- Suwon, Kyonggi-do
- Seoul, Seoul/Korea
- Seoul,
- Seoul,
- Badalona, Barcelona/Spain
- Madrid, Madrid/Spain
Descriptive Information | ||||
---|---|---|---|---|
Brief Title | The Bowel Research Collaborative Data Tracking System Implementation Study | |||
Official Title | The Bowel Research Collaborative Data Tracking System Implementation Study | |||
Brief Summary | The project's primary purpose is to establish a network of Hospice Palliative Care settings using a common and consistent method of assessing and documenting bowel functioning in order to be able to carry out future collaborative studies of constipation treatments. The secondary goal is to gather normative data on current bowel care function and outcomes of current treatments which can be used to determine sample size calculations for future controlled trials of bowel management protocols. In order to complete this goal the project requires a thorough assessment of current nursing practice in regard to bowel care. | |||
Detailed Description | Site assessment: Each site will be assessed as to their current bowel assessment and documentation methods, and their current bowel management strategy. Clinical practice leaders (nursing and physician) will be interviewed, and as many of the nurses as can be contacted will be asked to complete a brief questionnaire about bowel care at their site, with some focus groups being held in order to allow all staff to have input. A retrospective chart review will be carried out to include at least 30 patients to establish the current documentation standard and outcomes. The impact of bowel care on nursing practice will be assessed. Intervention: As a result of the assessments at all the sites and in collaboration with the site leaders, the research team will devise a common reporting and documentation system which will enable systematic collection of bowel outcomes data. It is intended that the Victoria Bowel Performance Scale will be introduced, in combination with other reporting tools specific to bowel management. The tools may vary from site to site depending on the context of care, for example an inpatient unit will have differing requirements to an outpatient clinic. However the goal is for required outcome data to be retrievable from charts from all settings in a consistent, complete and reliable way. Evaluation: Medical and nursing staff will be surveyed in the same way as in the initial assessment (interviews, questionnaires and focus groups), to assess the performance and acceptability of the modified reporting process. A second chart review will be undertaken when at least 30 patients have passed through the service. Outcomes from the chart reviews will be communicated back to care providers in order to give them feedback as to the quality of bowel care they are providing. Any further modifications to the data tracking system will be made so that by the end of the project the system is acceptable to all sites and functioning effectively, allowing the network of collaborating sites to proceed to the next step: clinical trials of different bowel care treatments. Demographic data recorded will be that required to determine comparability of cohorts with respect to risk for constipation and will include the following variables.
The primary outcome measures for bowel function for each patient will be the proportion of days with at least one bowel movement a day, and the proportion of patients with a bowel movement at least 40 % and at least 50% of days. The secondary outcome variables of the study will be use of enemas, suppositories or lactulose, and reported cramping and/or diarrhoea. Diarrhoea will be defined as either passage of watery stool at least once a day, or more than 3 bowel movements a day. These were the same outcome variables used in the docusate study. Sites will be grouped according to type of setting (hospice, PCU, home etc). Sites with very similar patients will be combined for statistical analysis (for example the two Vancouver residential hospices to which patients are referred through a common process and assigned to according to bed availability). Acceptability of the BPS will be assessed through a combination of questionnaires and focus groups with staff at sites which elect to pilot it after reviewing the results of the initial assessment. Their responses will be analysed using qualitative methodology. Staff will also be asked at the end of the study whether or not they would prefer to continue to use the BPS for routine clinical assessment or to revert to their previous method. The utility of the BPS as a suitable outcome measure for clinical trials of bowel management treatments will be explored by correlating the single item BPS score with the primary and secondary outcome variables. As scoring of the BPS is essentially a composite of multiple outcome variables, (bowel movement frequency, consistency, degree of sphincter control and associated symptoms such as cramping etc.) it is anticipated that the BPS will provide at least the same outcome information as the multiple individual variables, which are rarely fully documented. We hope that the BPS will provide more patient-centred and useful information to guide laxative treatment, as the tool is centred around the individual's "normal" bowel habit, rather than relying on arbitrarily defined norms. Data from all sites will be able to be pooled for this analysis. | |||
Study Type | Observational | |||
Study Design | Observational Model: Cohort Time Perspective: Retrospective | |||
Target Follow-Up Duration | Not Provided | |||
Biospecimen | Not Provided | |||
Sampling Method | Probability Sample | |||
Study Population | Patients receiving palliative care | |||
Condition | Constipation | |||
Intervention | Not Provided | |||
Study Groups/Cohorts |
| |||
Publications * | Hawley P, Barwich D, Kirk L. Implementation of the victoria bowel performance scale. J Pain Symptom Manage. 2011 Dec;42(6):946-53. doi: 10.1016/j.jpainsymman.2011.02.021. Epub 2011 May 26. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status | Completed | |||
Actual Enrollment | 533 | |||
Original Estimated Enrollment | 390 | |||
Actual Study Completion Date | February 2010 | |||
Actual Primary Completion Date | February 2010 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender |
| |||
Ages | Child, Adult, Older Adult | |||
Accepts Healthy Volunteers | No | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | Canada | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT00728975 | |||
Other Study ID Numbers | H08-01321 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement | Not Provided | |||
Responsible Party | Pippa Hawley, British Columbia Cancer Agency | |||
Study Sponsor | British Columbia Cancer Agency | |||
Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Investigators |
| |||
PRS Account | British Columbia Cancer Agency | |||
Verification Date | November 2018 |